{"name":"Context Therapeutics Inc.","slug":"context-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"Context Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for cancer. The company's pipeline includes two drug candidates, CT-95 and CTIM-76, both currently in Phase 1 trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":-36123615,"cash":65995228,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPMXpZdnNHUXAxMGw0TUtiZy1SZkhyZXZzbkxsd3plaXpnRGFndXhBbUtNSnJMQ0Y5UUFiVTNucU1OMGZBRHZnenVWeGpwQnpObFkyZVVFQ3dfODJRREIwd244VklPdHRXMHVJZG9SUGNDY0k1Y05tc19xZkgweGJOOTBVaTBlUUExRTk3T0lkcV9SWkNZUHpmU25pTUR5R0Z4YTNOR2NjUDhkS1JKdU9VR1U3OUUxSVJOV1FkVG5YWS0?oc=5","date":"2026-04-08","type":"pipeline","source":"Stock Titan","summary":"Food safety company Neogen taps biotech lawyer for legal, compliance post - Stock Titan","headline":"Food safety company Neogen taps biotech lawyer for legal, compliance post","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAJBVV95cUxOMmdCVU9paFIxNHVGSC00UzVuSGNzOV9jN2hTM1BvUHNtSWx6ZWFtVWJNNzBSUUZtNWloQUUtTi1ZS29xcFM1NkZoNm5EdEVmQmhMSGZsNHNiRGlTNnIxOGNSb3VWYmJoQkI1eXMwTEk2YVU3U3k3bEZDQmtMTXFRaUtfaU1rR1JCWE5XM1RsaDBKWW9xeUxSNGxhUFhRdkhSMTVwTjdQNUc1RktRTWVWY0FUOERoR0l1MzNvTHlYSGtUV3V4TlZKMmtiX2VsN3BxWTFQbkZpSnN5V3hEbjZlV2dlMHVzT3lMUzJNY3FvYXRENi1Bam9GaE1OQjFiUmtIdjhSZm5Tbnp2eFU0Zm1sT2dwRlpXWmx0bi1tMmlrNVZnWjZpNU16bA?oc=5","date":"2026-04-02","type":"regulatory","source":"GlobeNewswire","summary":"Context Therapeutics Announces CTIM-76 Receives FDA Fast - GlobeNewswire","headline":"Context Therapeutics Announces CTIM-76 Receives FDA Fast","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNWEgyc25zSHdrNHZNZGZOMkxLMnctaHJVQVNkcW5QVklyRHBEWVlFd05oY0xBb2ZvZXY5VnFGd2c0YnpWRDFmenJDT0tMVmVMeUxnS0RhRWRkVUZLc1BDYXUzbGNEamNIY0ZEUE1LSWpIV19oaXFtSnNRbVJzcDFiSWludDZMeUswLU4wSFctRUhxemptMEZ6MUZMU3ZPSDNCV214OS1IdnlIN3ZmNUlDWGlJQQ?oc=5","date":"2026-04-02","type":"regulatory","source":"Stock Titan","summary":"FDA grants Fast Track to Context Therapeutics (CNTX) CTIM-76 in platinum-resistant ovarian cancer - Stock Titan","headline":"FDA grants Fast Track to Context Therapeutics (CNTX) CTIM-76 in platinum-resistant ovarian cancer","sentiment":"neutral"},{"date":"2026-04-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgJBVV95cUxPS0p3bDFlZVVfc05mQ2hULUQzUEIwZnZEVWV4NVBJUGVMSGpRa3BaR2hfNFFMRmdFckNOOXFQQVcxUjJiMUhmcjVwLW11OUVOMU9zTW8tcXNxWU9UX2tWYzlLUUdMQ095WFZ3bzNOa2RXYUpNZVVZNC1sYlp6ajlLMFFlbHQwZjB5SE1mY3RfQndDQkRHVE1nR3VCOHh2S0l2WHdOTXhtOFQ3YUVUbDVxZndzS3doRTh6bHRJRExiVWc0S2R2eVF1bTdkLXRHY2tFVnFXSFRtYnRwMllEenFHWTR0TUNpLVlJa2RKLVVzeThzc0tzRWJvRkpWbFZCclNQdVBVc0FkOExiUFR0WU1qY1VjaFZ6Q1BJSDhyQi1kZVR3LXBfZDRWWWFqbUxkUQ?oc=5","date":"2026-03-25","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS), Nurix Therapeutics (NRIX) and Context Therapeutics (CNTX) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS), Nurix Therapeutics (NRIX) and Context Therapeuti","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxQTWt4bUR3Rkk2QXpXTS1HdFZvLURhemVMX011VXlZbm0td2JGY3BLUU9hZWxmZ1BoUF81a1pjSURFUjZHRTZIMU1yX0JRby1mS0QxcGxNdXVUMnNuSld4b3dUYVpGcFBSMXFxaTZtRk5HVVZmNWt2aklMRW5pVWgwQ2ItY3VtRGtYZDR2b2VPRktFLVdXT2VhbWMyeTNsbHBpOGlTLTNLNkR5WmpzODdBbWowZTBtcXVtRHF4ZUxWMUVOMVF1UlQ2OWN4Mm5QZDlBYUVPZFFaN1E0N1QwNy1xOQ?oc=5","date":"2026-03-23","type":"pipeline","source":"GlobeNewswire","summary":"Context Therapeutics Reports Full Year 2025 Operating and Financial Results - GlobeNewswire","headline":"Context Therapeutics Reports Full Year 2025 Operating and Financial Results","sentiment":"neutral"},{"date":"2026-03-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-23","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAJBVV95cUxOSzdxV0NQQ0tiR2pPZUF1a0MzTG1MTG1nVXBLSjRlMDV3bUc0dDVQR0pNRmZ1QU55Si0zazFfZHdaYjhicVhEYUJkM1kwcEc0VEF4bTlWUnlkalNMYVNUMTdWa09Qa3dLZjNtWlltREFqOTVHaWt5QTZHNlhKRzZwNlUtblp3LUp3aE56STA1c2lLR0RwYVdzWFB4UDVqYWFMVEdoX19OS2E0UFU1X1lkSjBOR1B3bzhubnA0dkJ0TkktNGg0WUc4bU9UUjFFcHhmWkdBYzZmYmt1OWVHZ3VPVEVpSUJMQWFMYmhteWdUY0syUzI5bks5d0ZqZ193X1A0dDZtdVREbFNxSks2dk00dy1VMUpWdFRQOWRxS0hSclc?oc=5","date":"2026-03-19","type":"pipeline","source":"GlobeNewswire","summary":"Context Therapeutics Announces Poster Presentation at the - GlobeNewswire","headline":"Context Therapeutics Announces Poster Presentation at the","sentiment":"neutral"},{"date":"2026-03-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-23","type":"deal","source":"simplywall.st","summary":"Context Therapeutics Insiders May Regret Not Buying More, Market Cap Hits US$151m - simplywall.st","headline":"Context Therapeutics Insiders May Regret Not Buying More, Market Cap Hits US$151m","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxObGk1YUwzS3lsTHFkOUNaenk5THBVWVhuV1RZZWkyWDVyZnljak5vWjFNd1Y1R2F2Mks1TjVNM3hXNkV0S1BERXZHWkU4dXNPRzNaTFhmZUY0Y18zemV3elctVTNJNkdKY1pfNkl5cUYtZ2NYbFZEbUZLbEFYcDZLaFZtZDZ2SHVWR2FiTG82X1hXU2FV?oc=5","date":"2026-01-19","type":"earnings","source":"Yahoo Finance","summary":"Unpacking Q3 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks - Yahoo Finance","headline":"Unpacking Q3 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks","sentiment":"neutral"},{"date":"2026-01-08","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-19","type":"pipeline","source":"simplywall.st","summary":"We're Hopeful That Context Therapeutics (NASDAQ:CNTX) Will Use Its Cash Wisely - simplywall.st","headline":"We're Hopeful That Context Therapeutics (NASDAQ:CNTX) Will Use Its Cash Wisely","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-36123615,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":65995228,"cashHistory":[],"totalAssets":68493768,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}